Pre-made Utomilumab benchmark antibody ( Whole mAb, anti-TNFRSF9/CD137 therapeutic antibody, Anti-ILA/4-1BB/CDw137 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Utomilumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Utomilumab is the proposed non-proprietary name for PF-05082566, an investigational immunotherapy and a fully human IgG2 agonist monoclonal antibody (mAb) that binds to the extracellular domain of human 4-1BB/CD137 with high affinity and specificity.
| Products Name (INN Index) | Pre-Made Utomilumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody |
|---|---|
| INN Name | Utomilumab |
| Target | TNFRSF9 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 6a3w:GH:DE:AB:JK/6mi2:DE:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Dana-Farber Cancer Institute,Immatics US,Kite Pharma,Kyowa Hakko Kirin,M. D. Anderson Cancer Center,Pfizer |
| Conditions Approved | NA |
| Conditions Active | Breast cancer,Oropharyngeal cancer,Solid tumours,B-cell lymphoma,Diffuse large B cell lymphoma,Follicular lymphoma,Ovarian cancer |
| Conditions Discontinued | Non-Hodgkin's lymphoma,Colorectal cancer |
| Development Tech | MorphoSys HuCAL Phage Display |
| Previous Name | NA |
| Gm Offical Target Name | TNFRSF9 |
| Package |
